Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders® - Arvinas ( NASDAQ:ARVN )
- ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid ( CSF ) exposure in subjects in both trials -
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
- ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease ...
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders® - Arvinas ( NASDAQ:ARVN )
NEW HAVEN, Conn., Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Arvinas, Inc. ( NASDAQ:ARVN ) , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that two presentations, including one e-poster session and one oral platform ...
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
NEW HAVEN, Conn., Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Arvinas, Inc. ( Nasdaq: ARVN ) , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that two presentations, including one e-poster session and one oral platform ...
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation - Arvinas ( NASDAQ:ARVN ) , Pfizer ( NYSE:PFE )
Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 Board authorizes stock repurchase program of up to $100 ...
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of ...
3 Magnificent S&P 500 Dividend Stocks Down as Much as 60% to Buy and Hold Forever
A good stock is an even better buy when it's on sale, even if your primary goal is immediate and reliable income.
Arvinas to Participate in Upcoming Investor Conferences - Arvinas ( NASDAQ:ARVN )
NEW HAVEN, Conn., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Arvinas, Inc. ARVN, a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in fireside chats at two upcoming investor conferences:
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Arvinas, Inc. ( Nasdaq: ARVN ) , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in fireside chats at two upcoming investor ...
Cascade Prodrug Inc. Appoints Industry Veterans Manuel ( Manny ) Litchman and Andres Gutierrez to Board of Directors
EUGENE, Ore., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Cascade Prodrug, Inc. ( "Cascade" ) , a biotechnology company focused on advancing novel Hypoxia Activated Therapies in oncology, today announced the appointment of Manuel ( Manny ) Litchman, M.D. and Andres Gutierrez M.D., Ph.D. to its Board of ...
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
- Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus ...
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles
NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.
Arvinas, Inc. ( ARVN ) Reports Q2 Loss, Misses Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of +3.45% and -53.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised
Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat
BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises
AMRN beats second-quarter estimates for earnings. Revenues rise year over year on strong licensing gains.
UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y
United Therapeutics' second-quarter earnings miss estimates, while revenues rise 12% on strong Tyvaso and other product sales.
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.
5 High-Yield Stock Picks to Add to Your Dividend Portfolio
It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth.
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer
CORT's relacorilant combo targets platinum-resistant ovarian cancer in new NDA, backed by positive ROSELLA study data.
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.
Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm - Arvinas ( NASDAQ:ARVN ) , Abacus Global Management ( NASDAQ:ABL )
NEW YORK, June 23, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Arvinas, Inc. ARVN, Semler Scientific Inc. SMLR, and Abacus Global Management, Inc.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Arvinas ( NASDAQ:ARVN ) , Merck & Co ( NYSE:MRK )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Wall Street Analysts Believe Arvinas ( ARVN ) Could Rally 89.85%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
- ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type ( also known as AITL ) and transformed follicular lymphoma ...
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences - Arvinas ( NASDAQ:ARVN ) , BioNTech ( NASDAQ:BNTX )
PALM BEACH, Fla., June 11, 2025 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Arvinas ( NASDAQ:ARVN ) , GSK ( NYSE:GSK )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Pfizer, Arvinas Breast Cancer Drug Cuts Progression Risk, Seeks FDA Approval - Arvinas ( NASDAQ:ARVN ) , Pfizer ( NYSE:PFE )
Vepdegestrant reduces disease progression risk by 43% versus fulvestrant in ESR1-mutated patients. Median PFS was 5 months with vepdegestrant versus 2.1 months with fulvestrant in the ESR1 subgroup. Get the Strategy to Trade Pre-Fed Setups and Post-Fed Swings-Live With Chris Capre on Wednesday, ...
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
- This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine ...
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association ( EHA ) Annual Meeting - Arvinas ( NASDAQ:ARVN )
- Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type ( AITL ) and transformed follicular lymphoma, and in combination with small molecule inhibitors in ...
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association ( EHA ) Annual Meeting
- Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type ( AITL ) and transformed follicular lymphoma, and in combination with small molecule inhibitors in ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN - Arvinas ( NASDAQ:ARVN )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ( "Arvinas" or the "Company" ) ARVN. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Algoma Steel Group ( NASDAQ:ASTL ) , Arvinas ( NASDAQ:ARVN )
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday. Shares of Science Applications International Corporation SAIC fell sharply in today's pre-market trading after the company reported first-quarter results.
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - Arvinas ( NASDAQ:ARVN ) , Pfizer ( NYSE:PFE )
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
• Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation • Vepdegestrant was generally well tolerated, with few ...
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
NEW HAVEN, Conn. and NEW YORK, May 31, 2025 ( GLOBE NEWSWIRE ) -- Arvinas, Inc. ( Nasdaq: ARVN ) and Pfizer Inc. ( NYSE: PFE ) today announced detailed results from the Phase 3 VERITAC-2 clinical trial ( NCT05654623 ) evaluating vepdegestrant monotherapy versus fulvestrant in adults with ...
